Enovis Co. (NYSE:ENOV) Shares Sold by Bank of Montreal Can

Bank of Montreal Can cut its position in Enovis Co. (NYSE:ENOV) by 5.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,963 shares of the company’s stock after selling 486 shares during the quarter. Bank of Montreal Can’s holdings in Enovis were worth $385,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Boone Capital Management LLC grew its stake in Enovis by 11.9% during the 4th quarter. Boone Capital Management LLC now owns 562,739 shares of the company’s stock worth $31,525,000 after purchasing an additional 60,008 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Enovis during the fourth quarter worth approximately $284,000. Goldman Sachs Group Inc. increased its stake in shares of Enovis by 5.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 534,179 shares of the company’s stock worth $29,925,000 after buying an additional 29,229 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Enovis in the fourth quarter valued at approximately $3,305,000. Finally, Quadrature Capital Ltd lifted its stake in Enovis by 175.5% in the fourth quarter. Quadrature Capital Ltd now owns 34,160 shares of the company’s stock worth $1,913,000 after acquiring an additional 21,760 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ENOV. Evercore ISI lowered their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. Needham & Company LLC dropped their price objective on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. JMP Securities assumed coverage on Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their price target on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $67.89.

Enovis Trading Down 0.1 %

Shares of Enovis stock opened at $38.72 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26. The company has a market capitalization of $2.12 billion, a P/E ratio of -25.81 and a beta of 1.91. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03. The company’s fifty day moving average is $43.20 and its two-hundred day moving average is $48.15.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.03. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The firm had revenue of $525.20 million for the quarter, compared to analysts’ expectations of $525.99 million. During the same quarter in the previous year, the firm posted $0.61 EPS. The firm’s revenue for the quarter was up 22.6% on a year-over-year basis. Analysts forecast that Enovis Co. will post 2.7 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.